Effect of immune depletion against FUVAC treatment
(A) Schedule of the CD4 or CD8 depletion. CT26-bearing mice were administrated with MDRVV or FUVAC on days 0, 2, and 4, and 200 μg of Isotype ctrl, anti-CD4, or anti-CD8 antibody was injected on days 3, 5, and 7. (B and C) Tumor growth curves of mice after the treatment of each inhibitor with MDRVV (B) or FUVAC (C). Mean tumor volume (mm3) ± SEM are shown (n = 6–7). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 (two-way ANOVA).